田中 謙太郎

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. osimertinib 40%
3. ErbB Receptors 32%
4. Small Cell Lung Carcinoma 31%
5. Protein-Tyrosine Kinases 25%
6. Mutation 21%
7. Platinum 18%
8. T-Lymphocytes 17%
9. Neoplasms 16%
10. Afatinib 15%
11. Cytokines 15%
12. Lung Neoplasms 15%
13. Therapeutics 15%
14. Apoptosis 14%
15. Nivolumab 14%
16. Regulatory T-Lymphocytes 13%
17. Adenocarcinoma of Lung 13%
18. Pemetrexed 13%
19. Drug Therapy 13%
20. Idiopathic Pulmonary Fibrosis 12%
21. Survival 11%
22. Progression-Free Survival 10%
23. Pleural Effusion 9%
24. erbB-1 Genes 9%
25. Dendritic Cells 9%
26. Th17 Cells 9%
27. rovalpituzumab tesirine 8%
28. Calreticulin 8%
29. Gefitinib 8%
30. Helper-Inducer T-Lymphocytes 8%
31. Japan 8%
32. RC-1291 8%
33. Th1 Cells 8%
34. Bronchoalveolar Lavage Fluid 7%
35. Safety 7%
36. Autoimmunity 7%
37. Propensity Score 7%
38. anamorelin 7%
39. Albumins 6%
40. pembrolizumab 6%
41. Interleukin-10 6%
42. delta protein 6%
43. Phenotype 6%
44. Suppressor of Cytokine Signaling 1 Protein 6%
45. atezolizumab 6%
46. Nuclear Receptor Coactivator 3 6%
47. neuromedin U 6%
48. CH5424802 5%
49. High-Throughput Nucleotide Sequencing 5%
50. Anaplastic Lymphoma Kinase 5%